Icariside II prevents kidney fibrosis development in chronic kidney disease by promoting fatty acid oxidation
Phytotherapy Research · 2024
DOI: 10.1002/ptr.8085 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytotherapy Research, 2024. Verfasst von Meng Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Kidney Diseases, Renal Insufficiency, Chronic, Epoxy Compounds, Flavonoids. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Sailing Program.
Abstract (Originalsprache)
Renal interstitial fibrosis (RIF) is the main pathological basis for the progression of chronic kidney disease (CKD), however, effective interventions are limited. Here, we investigated the effect of Icariside II (ICA‐II) on RIF and explored the underlying mechanisms. Rats receiving 5/6 ablation and infarction (A/I) surgery were gavaged with ICA‐II (5 or 10 mg/kg) for 8 weeks. In vitro, TGF‐β1‐stimulated NRK‐52E cells were treated with ICA‐II and (or) oleic acid, etomoxir, ranolazine, fenofibrate, and GW6471. The effects of ICA‐II on RIF, fatty acid oxidation, lipid deposition, and mitochondrial function were determined by immunoblotting, Oil red O staining, colorimetric, and fluorometric assays. Using adeno‐associated virus injection and co‐culture methods, we further determined mechanisms of ICA‐II anti‐RIF. ICA‐II ameliorated the fibrotic responses in vivo and in vitro. RNA‐seq analysis indicated that ICA‐II regulated fatty acid degradation and PPAR pathway in 5/6 (A/I) kidneys. ICA‐II attenuated lipid accumulation and up‐regulated expression of PPARα, CPT‐1α, Acaa2, and Acadsb proteins in vivo and in vitro. Compared to ICA‐II treatment, ICA‐II combined with Etomoxir exacerbated mitochondrial dysfunction and fibrotic responses in TGF‐β‐treated NRK‐52E cells. Importantly, we determined that ICA‐II improved lipid metabolism, fatty acid oxidation, mitochondrial function, and RIF by restoring PPARα. Co‐culture revealed that ICA‐II decreased the expression of Fibronectin, Collagen‐I, α‐SMA, and PCNA proteins in NRK‐49F cells by restoring PPARα of renal tubular cells. ICA‐II may serve as a promising therapeutic agent for RIF in 5/6 (A/I) rats, which may be important for the prevention and treatment of CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Key Laboratory of Liver and Kidney Diseases, Ministry of Education, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- TCM Institute of Kidney Disease, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Department of Traditional Chinese Medicine, Huadong Hospital Affiliated to Fudan University, Shanghai, China.
Förderung
- National Natural Science Foundation of China
- Shanghai Sailing Program
Zitieren
APA
Wang, M., Wang, J., Wang, L., Feng, X., Qian, Y., Ye, C., & Wang, C. (2024). Icariside II prevents kidney fibrosis development in chronic kidney disease by promoting fatty acid oxidation. Phytotherapy Research. https://doi.org/10.1002/ptr.8085
Vancouver
Wang M, Wang J, Wang L, Feng X, Qian Y, Ye C, et al. Icariside II prevents kidney fibrosis development in chronic kidney disease by promoting fatty acid oxidation. Phytotherapy Research. 2024. doi:10.1002/ptr.8085
BibTeX
@article{Wang2024,
author = {Wang, Meng and Wang, Jing and Wang, Lingchen and Feng, Xiaoxuan and Qian, Yiling and Ye, Chaoyang and Wang, Chen},
title = {Icariside II prevents kidney fibrosis development in chronic kidney disease by promoting fatty acid oxidation},
journal = {Phytotherapy Research},
year = {2024},
doi = {10.1002/ptr.8085}
}
EUVIMED